USD Weakens Against EUR on Pharming Q3 Revenue Beat

While not directly forex-related, Pharming Group's strong Q3 2025 results showing 30% revenue growth to $97.3 million could indirectly impact USD crosses as the company reports in US dollars but operates globally. The pharmaceutical firm's RUCONEST revenue jumped 29% to $82.2 million, while Joenja revenue surged 35% to $15.1 million, reflecting robust international sales that may require currency hedging. The FDA's priority review for their pediatric treatment could further boost dollar-denominated revenues. Such strong corporate earnings from international firms often influence currency flows as companies manage cross-border transactions and repatriate profits. EUR/USD and GBP/USD could see modest impacts as European investors assess the earnings. However, direct forex market impact remains limited without specific guidance on currency exposure or hedging activities from the company.